Improving T cell killing and understanding senescence: Possible roles for TP53 in cancer immunotherapy.

Authors :: Levine AJ
Source :: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 Mar 19; Vol. 121 (12), pp. e2402533121. Date of Electronic Publication: 2024 Mar 11.
Publication Year :: 2024
Abstract: Competing Interests: Competing interests statement:A.J.L. is a consultant for Chugai Pharmaceutical company. He is a founder, board member and consultant at PMV Pharma, which produces small molecules that reactivate p53 mutant proteins and produce wild type proteins. He is a board member of GeneCentric a cancer RNA diagnostic company. And he consults for ROME (autoimmunity), and WCG (an IRB company).

Subjects :: Humans
Tumor Suppressor Protein p53 genetics
T-Lymphocytes
Immunotherapy
Cell Death
Cell- and Tissue-Based Therapy
Receptors, Chimeric Antigen
Neoplasms genetics
Neoplasms therapy

Language :: English
ISSN :: 1091-6490
Volume :: 121
Issue :: 12
Database :: MEDLINE
Journal :: Proceedings of the National Academy of Sciences of the United States of America
Publication Type :: Academic Journal
Accession number :: 38466858
Full Text :: https://doi.org/10.1073/pnas.2402533121

Full Text Access

Tools